Restricted accessResearch articleFirst published online 2025-12
Elucidating Genetic and Immunological Pathways Mediated by Sodium-Glucose Transporter 2 Inhibitors in Reducing Gout Risk: A Two-Step Mendelian Randomization Study
While sodium-glucose transporter 2 inhibitors (SGLT2i) demonstrate urate-lowering effects, their causal role in Gout prevention remains controversial. This study employs advanced Mendelian randomization (MR) techniques to dissect immune-mediated mechanisms underlying this relationship. Using bidirectional two-sample MR and mediation analysis, we analyzed genetic instrument variables for SGLT2i (10 single-nucleotide polymorphisms, F-statistic >20), Gout risk (6,810 cases/477,788 controls), and 731 immune cell phenotypes. Pleiotropy and heterogeneity were also assessed to ensure robustness. The study confirmed a significant indirect effect of SGLT2i, which exhibited a 2.6% reduced Gout risk (Odds Ratio [OR]: 0.9738, 95% confidence interval [CI] = 0.9623, 0.9854, P = 1.12e-05). Thirty-five immune cell phenotypes were identified as significantly affecting Gout development, with key phenotypes such as CD86 on myeloid Dendritic cell (DC) (OR: 0.9966; 95% CI = 0.9930, 0.9995), contributing to 12.8% of the overall mediation effect. No evidence of heterogeneity or pleiotropy was detected and reverse-direction MR corroborated these findings. Our study first established SGLT2i as Gout-protective agents through DC-mediated immunomodulation, offering mechanistic insights for targeted prevention strategies in clinical practice.
YokoseC, McCormickN, AbhishekA, et al.The clinical benefits of sodium-glucose cotransporter type 2 inhibitors in people with gout. Nat Rev Rheumatol, 2024; 20(4):216–231; doi: 10.1038/s41584-024-01092-x
YokoyamaS, NakagawaC, UnoT, HosomiK. Evaluating the associated hyperuricemia risk with sodium-glucose cotransporter 2 inhibitors: A sequence symmetry analysis using the Japanese administrative claims database. Biol Pharm Bull, 2024; 47(11):1851–1857; doi: 10.1248/bpb.b24-00330
4.
SubramanianA, GokhaleK, SainsburyC, et al.Sodium-glucose cotransporter-2 inhibitors and the risk of gout in patients with type 2 diabetes mellitus: A propensity score-matched, new-user design study with an active comparator using the IQVIA Medical Research Data UK database. Diabetes Obes Metab, 2023; 25(1):156–165; doi: 10.1111/dom.14858
5.
ChungMC, HungPH, HsiaoPJ, et al.Association of sodium-glucose transport protein 2 inhibitor use for type 2 diabetes and incidence of Gout in Taiwan. JAMA Netw Open, 2021; 4(11):e2135353; doi: 10.1001/jamanetworkopen.2021.35353
6.
de LimaJD, de PaulaAGP, YuasaBS, et al.Genetic and epigenetic regulation of the innate immune response to Gout. Immunol Invest, 2023; 52(3):364–397; doi: 10.1080/08820139.2023.2168554
7.
SoAK, MartinonF. Inflammation in gout: Mechanisms and therapeutic targets. Nat Rev Rheumatol, 2017; 13(11):639–647; doi: 10.1038/nrrheum.2017.155
8.
GBD 2021 Gout Collaborators. Global, regional, and national burden of gout, 1990-2020, and projections to 2050: A systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol, 2024; 6(8):e507–e517; doi: 10.1016/S2665-9913(24)00117-6
9.
ZhangY, LiuW, LaiJ, et al.Genetic associations in ankylosing spondylitis: Circulating proteins as drug targets and biomarkers. Front Immunol, 2024; 15:1394438; doi: 10.3389/fimmu.2024.1394438
10.
LiY, ZhuangZ, SiH, et al.Causal associations of cognitive reserve and hierarchical aging-related outcomes: A two-sample mendelian randomization study. Biol Res Nurs, 2025; 27(1):5–16; doi: 10.1177/10998004241274271
11.
LiJ, YuY, SunY, et al.SGLT2 inhibition, circulating metabolites, and atrial fibrillation: A Mendelian randomization study. Cardiovasc Diabetol, 2023; 22(1):278; doi: 10.1186/s12933-023-02019-8
12.
UusimaaJ, KettunenJ, VariloT, et al.Finnish genetic heritage in 2022, from diagnosis to translational research. Dis Model Mech, 2022; 15(10):dmm049490; doi: 10.1242/dmm.049490
13.
SkrivankovaVW, RichmondRC, WoolfBAR, et al.Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: The STROBE-MR statement. JAMA, 2021; 326(16):1614–1621; doi: 10.1001/jama.2021.18236
14.
GTEx Consortium. The GTEx consortium atlas of genetic regulatory effects across human tissues. Science, 2020; 369(6509):1318–1330; doi: 10.1126/science.aaz1776
15.
VõsaU, ClaringbouldA, WestraHJ, et al.; i2QTL Consortium. Large-scale cis- and trans-eQTL analyses have identified thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet, 2021; 53(9):1300–1310; doi: 10.1038/s41588-021-00913-z
16.
CaoRR, YuXH, XiongMF, et al.Immune factors have complex causal regulatory effects on bone mineral density. Front Immunol, 2022; 13:959417; doi: 10.3389/fimmu.2022.959417
17.
BurgessS, ThompsonSG, CRP CHD Genetics Collaboration. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol, 2011; 40(3):755–764; doi: 10.1093/ije/dyr036
18.
DönertaşHM, FabianDK, ValenzuelaMF, et al.Common genetic associations between age-related diseases. Nat Aging, 2021; 1(4):400–412; doi: 10.1038/s43587-021-00051-5
19.
OrrùV, SteriM, SidoreC, et al.Complex genetic signatures in immune cells underlie autoimmunity and inform therapies. Nat Genet, 2020; 52(10):1036–1045; doi: 10.1038/s41588-020-0684-4
20.
ZhangJ, FanW, SuC, JinZ, Linzhu. Influence of immune cells and inflammatory factors on Alzheimer’s disease axis: Evidence from mediation Mendelian randomization study. BMC Neurol, 2025; 25(1):49; doi: 10.1186/s12883-025-04057-z
21.
CarterAR, SandersonE, HammertonG, et al.Mendelian randomization for mediation analysis: Current methods and challenges for implementation. Eur J Epidemiol, 2021; 36(5):465–478; doi: 10.1007/s10654-021-00757-1
22.
XuQ, NiJJ, HanBX, et al.Causal relationship between gut microbiota and autoimmune diseases: A two-sample Mendelian randomization study. Front Immunol, 2021; 12:746998; doi: 10.3389/fimmu.2021.746998
23.
LvX, ShangY, NingY, et al.Pharmacological targets of SGLT2 inhibitors in IgA nephropathy and membranous nephropathy: A Mendelian randomization study. Front Pharmacol, 2024; 15:1399881; doi: 10.3389/fphar.2024.1399881
24.
LaiSW, HwangBF, KuoYH, et al.Sodium-glucose cotransporter-2 inhibitor use and risk of gout: A systematic review and meta-analysis. Front Endocrinol (Lausanne), 2023; 14:1158153; doi: 10.3389/fendo.2023.1158153
25.
JasleenB, VishalGK, SameeraM, et al.Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors: Benefits versus risk. Cureus, 2023; 15(1):e33939; doi: 10.7759/cureus.33939
DoehnerW, AnkerSD, ButlerJ, et al.Uric acid and SGLT2 inhibition with Empagliflozin in heart failure with preserved ejection fraction: The EMPEROR-Preserved trial. JACC Heart Fail, 2024; 12(12):2057–2070; doi: 10.1016/j.jchf.2024.08.020
28.
CaiX, YangW, GaoX, et al.Association between SGLT2 inhibitor dosage and weight reduction in patients with type 2 diabetes: A meta-analysis. Obesity (Silver Spring), 2018; 26(1):70–80; doi: 10.1002/oby.22066
29.
ToyokiD, ShibataS, Kuribayashi-OkumaE, et al.Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2. Am J Physiol Renal Physiol, 2017; 313(3):F826–F834; doi: 10.1152/ajprenal.00012.2017
30.
SuijkDLS, van BaarMJB, van BommelEJM, et al.SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function. Clin J Am Soc Nephrol, 2022; 17(5):663–671; doi: 10.2215/CJN.11480821
31.
BerezinAE, BerezinaTA. Plausible prediction of renoprotective effects of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney diseases. J Int Med Res, 2024; 52(2):3000605241227659; doi: 10.1177/03000605241227659
32.
Rodríguez-MiguelA, Fernández-FernándezB, OrtizA, et al.Glucose-Lowering drugs and primary prevention of chronic kidney disease in type 2 diabetes patients: A real-world primary care study. Pharmaceuticals (Basel), 2024; 17(10):1299; doi: 10.3390/ph17101299
33.
FralickM, ChenSK, PatornoE, KimSC. Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study. Ann Intern Med, 2020; 172(3):186–194; doi: 10.7326/M19-2610
34.
HirumaS, ShigiyamaF, HisatakeS, et al.A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: The ASSET study. Cardiovasc Diabetol, 2021; 20(1):32; doi: 10.1186/s12933-021-01228-3
35.
XuL, NagataN, ChenG, et al.Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high fat diet. BMJ Open Diabetes Res Care, 2019; 7(1):e000783; doi: 10.1136/bmjdrc-2019-000783
36.
ZhouJ, LiuX, ChouOH, et al.Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes. Rheumatology (Oxford), 2023; 62(4):1501–1510; doi: 10.1093/rheumatology/keac509
37.
KimSK. The mechanism of NLRP3 inflammasome activation and pathogenic implications in the pathogenesis of gout. J Rheum Dis, 2022; 29(3):140–153; doi: 10.4078/jrd.2022.29.3.140
38.
ZhangR, XieQ, LuX, et al.Research advances on the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus. Diabetol Metab Syndr, 2024; 16(1):99; doi: 10.1186/s13098-024-01325-9
39.
ZiX, SuR, SuR, et al.Elevated serum IL-2 levels and Th17/Treg imbalance are associated with gout. Clin Exp Med, 2024; 24(1):9; doi: 10.1007/s10238-023-01253-4
40.
YuH, XueW, YuH, et al.Single-cell transcriptomics revealed variations in monocyte and Treg levels between gout flares and remission. JCI Insight, 2023; 8(23):e171417; doi: 10.1172/jci.insight.171417
41.
NguyenHO, TiberioL, FacchinettiF, et al.Modulation of human dendritic cell functions by phosphodiesterase-4 inhibitors: Potential relevance for the treatment of respiratory diseases. Pharmaceutics, 2023; 15(9):2254; doi: 10.3390/pharmaceutics15092254
42.
ChangJG, TuSJ, HuangCM, et al.Single-cell RNA sequencing of immune cells in patients with acute gout. Sci Rep, 2022; 12(1):22130; doi: 10.1038/s41598-022-25871-2
43.
AlshahraniMY, Al AmriFS, AlzahraniMA, et al.Metformin ameliorates diabetes-induced hepatic ultrastructural damage and the immune biomarker CD86 and inflammation in rats. Ultrastruct Pathol, 2025; 49(1):58–66; doi: 10.1080/01913123.2024.2440479
44.
Aragón-HerreraA, Moraña-FernándezS, Otero-SantiagoM, et al.The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats. Biomed Pharmacother, 2023; 161:114535; doi: 10.1016/j.biopha.2023.114535
45.
WangN, WangJ, JiangR. Effects of IL-10 on OX62, MHC-II and CD86 in bone marrow DCs in rats with organophosphate poisoning. Exp Ther Med, 2018; 15(2):1906–1909; doi: 10.3892/etm.2017.5629
46.
BaileyCJ. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes Obes Metab, 2019; 21(6):1291–1298; doi: 10.1111/dom.13670
